Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients

被引：10

作者：

Canestri, Ana ^{[1
,3
]}

Krivine, Anne ^{[2
]}

Assoumou, Lambert ^{[3
]}

Le Corre, Monique ^{[4
]}

Rozenberg, Flore ^{[2
]}

Marcelin, Anne-Genevieve ^{[3
,5
,6
]}

Schneider, Luminita ^{[3
]}

Samri, Assia ^{[4
]}

Carcelain, Guislaine ^{[5
,7
]}

Autran, Brigitte ^{[5
,7
]}

Katlama, Christine ^{[3
,5
]}

Guihot, Amelie ^{[5
,7
]}

机构：

[1] Hop La Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, F-75013 Paris, France

[2] Hop St Vincent De Paul, AP HP, Virol Lab, Paris, France

[3] INSERM, UMR 943, Paris, France

[4] INSERM, UMR S945, Paris, France

[5] Univ Paris 06, Paris, France

[6] Hop La Pitie Salpetriere, AP HP, Virol Lab, F-75013 Paris, France

[7] Hop La Pitie Salpetriere, AP HP, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France

来源：

AIDS | 2010年 / 24卷 / 18期

关键词：

VIRUS; CCR5; DEFICIENCY;

D O I：

10.1097/QAD.0b013e3283402bc1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune changes induced by the CCR5 antagonist maraviroc raise the question of an impairment of responses to vaccines. We evaluated the immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine in HIV-1-infected patients with suppressed HIV viremia with or without a maraviroc-containing regimen. Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine. Copyright © Lippincott Williams & Wilkins.

引用

页码：2887 / 2889

页数：3

共 7 条

[1] Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus [J].

Dawson, TC ;

Beck, MA ;

Kuziel, WA ;

Henderson, F ;

Maeda, N .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (06) :1951-1959

[2] Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].

Dorr, P ;

Westby, M ;

Dobbs, S ;

Griffin, P ;

Irvine, B ;

Macartney, M ;

Mori, J ;

Rickett, G ;

Smith-Burchnell, C ;

Napier, C ;

Webster, R ;

Armour, D ;

Price, D ;

Stammen, B ;

Wood, A ;

Perros, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732

[3]

Kendal A.P., 1982, CONCEPTS PROCEDURES

[4] A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis [J].

Kindberg, Elin ;

Mickiene, Aukse ;

Ax, Cecilia ;

Akerlind, Britt ;

Vene, Sirkka ;

Lindquist, Lars ;

Lundkvist, Ake ;

Svensson, Lennart .

JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (02) :266-269

[5]

LAUNAY O, 2010, 17 C RETR OPP INF SA

[6] Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: A meta-analysis of 4 cohorts in the US epidemic [J].

Lim, Jean K. ;

Louie, Christine Y. ;

Glaser, Carol ;

Jean, Cynthia ;

Johnson, Bernard ;

Johnson, Hope ;

McDermott, David H. ;

Murphy, Philip M. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (02) :262-265

[7] A note of caution on yellow fever vaccination during maraviroc treatment: a hypothesis on a potential dangerous interaction [J].

Roukens, Anna H. ;

Visser, Leo G. ;

Kroon, Frank A. .

AIDS, 2009, 23 (04) :542-543

← 1 →